Compliance, CMC & Toxicology Consulting Service
Inquiry
In the high-stakes arena of drug development, navigating the intersection of chemistry, manufacturing, and controls (CMC), non-clinical toxicology, and global regulatory compliance is the most significant hurdle to market entry. Protheragen provides an integrated consultancy framework designed to de-risk biological assets from discovery through to biologics license applications (BLA) and new drug applications (NDA). By harmonizing scientific rigor with strategic Regulatory Intelligence, we ensure that therapeutic innovations meet the stringent demands of the FDA, EMA, and NMPA without compromising development velocity.
Comprehensive Compliance, CMC & Toxicology Consulting Services for Global Bio-Innovation
Protheragen provides an integrated suite of Clinical Research Services, ensuring high-efficiency translation from non-clinical safety data to First-in-Human (FIH) trials and subsequent market authorization. Our expertise is focused on the following key service pillars:
- Translational Safety & Clinical Toxicology
- IND/CTA Submission Support: Comprehensive evaluation and authoring of the non-clinical safety package required for global regulatory filings.
- Clinical Data Due Diligence: Expert review and gap analysis of toxicology data generated during Phase I and Phase II trials to ensure continued safety.
- Clinical Hold Resolution: Strategic development of toxicological justifications and corrective action plans to address agency concerns and lift clinical holds.
- Benefit-Risk Profiling: Quantitative safety-efficacy assessments tailored to specific patient populations to support dose-escalation and pivotal trial designs.
- Clinical CMC & Quality Excellence
Our expert SMEs deliver advanced impurity profiling and qualification in strict accordance, complemented by comprehensive nitrosamine risk mitigation and the establishment of acceptable intake (AI) levels. Furthermore, we implement rigorous stability and formulation strategies, utilizing in-depth degradation pathway analysis to guarantee drug product integrity across the global clinical supply chain.
- Regulatory Strategy & Agency Interaction
- Expedited Pathway Design: Strategic planning and authoring for fast track, breakthrough therapy, and priority review status.
- Global Regulatory Intelligence: Real-time monitoring and adaptation of development plans to meet shifting FDA, EMA, and NMPA compliance standards.
- Agency Engagement: Leading and managing Pre-IND meetings and scientific advice sessions, providing expert representation during regulatory audits and information requests (IRs).
- Product Safety & Material Evaluation
We employ a proactive toxicological defense framework. By rigorously auditing the chemical interface between therapeutics and container closures, we systematically de-risk molecular integrity and neutralize leaching hazards before they manifest as regulatory liabilities during clinical trials. Our team develops robust biocompatibility frameworks and study protocols for combination products (e.g., pre-filled pens) in strict alignment.
Contact Our Team for a Preliminary Gap Analysis and Strategy Session.
Workflow
Our systematic five-step approach ensures every project milestone is met with documented precision and scientific integrity:
Applications
Our expertise spans the most complex and innovative therapeutic modalities in the industry, addressing the unique safety and quality challenges inherent to each:
- Biologics & Biosimilars: We deliver granular regulatory intelligence for complex biologics, encompassing monoclonal antibodies (mAbs) and recombinant proteins. Our core value lies in ensuring biosimilars achieve high molecular-level consistency with reference products through precise physicochemical characterization and forward-looking immunogenicity risk assessment, thereby enabling robust passage of global regulatory quality consistency reviews.
- Small Molecule Anti-obesity Drugs & Metabolic Therapeutics: We provide high-level regulatory navigation for the next generation of oral metabolic modulators. Our expertise centers on optimizing the development trajectory of small-molecule GLP-1 receptor agonists and multi-receptor poly-agonists, ensuring that early-stage chemical stability and pharmacokinetic profiling align with rigorous global registration benchmarks.
- Advanced Anti-Drug Delivery Systems: We manage the safety and CMC challenges of novel delivery technologies, such as sustained-release microspheres, nanoparticle carriers, and targeted delivery ligands, ensuring optimal pharmacokinetic profiles and material biocompatibility.
Advantages
First-Pass Approval Focus
We employ a "Compliance by Design" philosophy, embedding regulatory expectations into the earliest stages of CMC and toxicology planning. This proactive strategy significantly minimizes the catastrophic risk of "Refusal to File" or "Clinical Hold" letters, which can derail funding and investor confidence. Our goal is to ensure that your first submission is your final submission before approval.
Unrivaled Scientific Depth
Our consulting bench is comprised of PhD-level specialists, many of whom have spent navigating the complexities of biologics, biosimilars, and advanced therapy medicinal products (ATMPs). This deep-seated expertise allows us to provide nuanced interpretations of ambiguous regulatory guidance, ensuring your program remains scientifically robust under the closest scrutiny.
Strategic Cost Efficiency
By managing CMC, toxicology, and regulatory strategy under a single expert umbrella, Protheragen eliminates these inefficiencies. Our holistic oversight ensures that every study performed serves a dual purpose: advancing the science and satisfying the regulator, thereby maximizing your R&D budget.
Contact Our Team for More Information and to Discuss Your Project.
Customer Review
Optimizing Oral Bioavailability in Metabolic Candidates
"Protheragen was the turning point for our Phase I metabolic program. When we encountered unexpected CMC hurdles regarding the stability and oral bioavailability of our lead small molecule, their team provided a validated formulation and analytical solution that satisfied the FDA's concerns within weeks. Their expertise in metabolic pathways makes them a true extension of our R&D team."
Dr. Jo*** St**
Managing Chronic Safety for Anti-obesity Innovators
"The regulatory landscape for long-term anti-obesity treatments is rigorous, but Protheragen kept us ahead of the curve. Their toxicological strategy for our oral small molecule agonist was robust and innovative, addressing cardiovascular safety and long-term exposure requirements so effectively that we moved into pivotal trials faster."
Dr. El** Ro***
Frequently Asked Questions
-
Is your CMC support limited to small molecules?
No, while we have deep roots in synthetic chemistry, we also specialize in the far more complex landscapes of biologics and ATMPs. We address the stringent CMC requirements for cell and gene therapies, including potency assay development, viral clearance validation, and comparability protocols that are critical for these innovative modalities.
-
How do you ensure the quality of CRO-generated data?
We act as your technical eyes and ears through rigorous protocol review, on-site or remote study monitoring, and comprehensive raw data auditing. This oversight ensures that third-party CROs maintain full GLP/GMP compliance and that the resulting data is of sufficient quality to withstand the most rigorous regulatory inspections.
-
How can we initiate a project?
Initiation is seamless: you can reach out through our secure inquiry portal to schedule an introductory consultation. During this session, we will define your project scope, identify immediate regulatory hurdles, and outline a preliminary gap analysis to align our services with your specific clinical and commercial objectives.
Protheragen is committed to transforming your scientific breakthroughs into market-ready therapeutics. Our integrated approach to compliance, CMC, and toxicology is the catalyst your pipeline needs to succeed in a complex global market. We invite you to contact us today and discover how our specialized expertise can streamline your regulatory journey and bring your vision to life.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.